ESVEM TRIAL :

REFERENCES:

Circulation:1989;79:1354-1360
Circulation:1993;87:323-329
Circulation:1995;91:1070-1076
Circulation:1995;91:1988-1995

NEJM: 1993:329:445-451 & 452-458

In patients with sustained VT or those who survived  sudden death EP & Holter do not differ in their overall mortality reduction but one may reach the decision faster with EP. Sotalol did improve survival in patients with arrhythmias and was better than mexelitine, imipramine, propafenone, quinidine, pirmenol & procainamide.